

The ALICE RAP Global Science Group – Addiction research around the world

What is the Global Science Group?

The ALICE RAP Global Science Group (or GSG) was created recognising that the project needs to be informed by academic endeavours from outside of Europe in order to stay at the forefront of addiction research, as well as to contribute to the global scientific and political view of the topics we study. The GSG is a group of renowned scientists from across the globe, experts in a range of topics and coming from a number of different disciplines and perspectives. Between them, they have contributed over 2000 academic journal publications, books and chapters, principally on addiction-related topics. They all participate in varied research initiatives, are connected to different scholarly and research networks and represent a valuable source of knowledge of expertise for any and all ALICE RAP scientists.

What are the GSG doing in ALICE RAP?

Since the kick-off meeting of the project, members of the Global Science Group have been affiliated to different Areas of ALICE RAP, where they participate more closely with this project work. The GSG join 3 of our 5 annual plenary meetings and come together at some point during each of these to report to the project leaders, support the development of the project and plan the on-going collaboration.

The roles of the GSG in ALICE RAP include:

- Scanning the horizon – much of the latest GSG meeting was taken up with discussions of what the emerging challenges are in the addiction field and how different regions of the world are approaching these.
- Feedback on AR research – Members of the GSG are excited by the research being carried out in AR and offered themselves as sounding boards to the AR scientists to make comments or suggestions on research questions and approaches.
- Internal peer-review – the GSG members are in a good position to support any AR scientists who would like an internal peer review of publications or policy recommendations prior to submission.

You can contact any of the GSG members whose profiles appear below via the coordination team or by logging into the ALICE RAP website and accessing the [participants' contact details](#).

The GSG Members (in alphabetical order):



Dr. Guilherme Borges is a psychologist and epidemiologist, based in the Instituto Nacional de Psiquiatria Ramón de la Fuente Muñiz, Mexico (UNAM-Mexico), and with research and teaching affiliations to other academic institutions in Mexico, Brazil and the USA in the fields of Psychology, Epidemiology, Social Medicine and Public Health. His specific research interests include the scales and dimensions of alcohol use disorders and alcohol and drug use in relation to violence and suicide. He is part of the Expert Group Core Member in the Alcohol Use Expert Group, Global Burden of Diseases, Injuries, and Risk Factors Study (GBD Study).

Prof. Ron Borland is a behavioural scientists and the Nigel Gray Distinguished Fellow in Cancer Prevention at the Cancer Council Victoria. He is one of the Principal Investigators of the International Tobacco Control Policy Evaluation Project: an international collaboration currently active in over 20 countries. His work is designed to understand the impact on smokers of tobacco control policies, to help design better systems for regulating tobacco, and to research mass-disseminable strategies for helping smokers quit. He is currently developing a comprehensive theory of Hard to Change Behaviour based largely on the challenges of smoking cessation.




Prof. Sir Ian Gilmore (chair of the GSG) is immediate past-president of the British Royal College of Physicians and current president of the British Society of Gastroenterology. He is an honorary consultant physician at the Royal Liverpool University Hospital, specializing in liver disease, with particular interest in harms related to alcohol use and strongly supports minimum unit pricing as an effective regulation to reduce these. He chairs the multi-agency group, the UK Alcohol Health Alliance and has also been appointed as Chair of the European Alcohol and Health Forum Science Group.

Dr. Bridget Grant is a psychologist and epidemiologist, and Chief of the Laboratory of Epidemiology at the U.S. National Institute on Alcohol Abuse and Alcoholism (NIAAA) since 2003. She reviews for over 30 professional journals and is an Editorial Board Member of Journal of Studies on Alcohol and Drug and Alcohol Dependence and Member of the Expert Panel on Co-occurring Disability Determination at the Substance Abuse and Mental Health Services Administration since 2006. Her field of interest is alcohol related issues.




Prof. Ting-Kai (TK) Li trained as a medic, biochemist and geneticist in USA and Sweden and has held professorships and directorial roles in several academic institutions. He was Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA, USA) between 2002-2008, and is currently working part-time at Duke University as Professor of Psychiatry and Behavioral Sciences. The major focus of Dr. Li's research has been in the structure, function and genetic variants of the enzymes of human alcohol metabolism, the genetics of alcoholism and of different alcohol-liking and seeking behaviours.

Prof. Peter M. Miller, holds the chair in Psychiatry and Behavioral Sciences at the Center for Drug and Alcohol Programs at the Medical University of South Carolina. He is an experienced clinical psychologist, as well as researcher and teacher, who specializes in addictive behaviour patterns. His current research focuses on alcohol, tobacco and substance abuse screening and intervention in medical and dental settings. Dr. Miller is Editor-in-Chief of two international research journals, serves on several editorial boards and is President of the International Society of Addiction Journal Editors (ISAJE).



Prof. Juan Negrete trained as a physician in Argentina and specialised in psychiatry in Canada. He was formerly Professor of Psychiatry at University of Toronto and First Head of the Addiction Psychiatry Program, as well as founding Director of the Addictions Unit in Montreal General Hospital. He has also served in directorial positions in numerous associations on the study of addictions and consulted for PAHO on mental health, alcoholism and other drug dependences. He is currently Emeritus Professor of Medicine (Psychiatry) at McGill University. His major research interest is addictions and concurrent disorders.

Dr. Charles Parry is a Clinical and Research Psychologist, and Director of the South African Medical Research Council's Alcohol & Drug Abuse Research Unit (ADARU), which runs around 20 South African- or USA-funded research projects. He was educated in South Africa and the USA in Mathematical Statistics, Clinical Psychology and Community Psychology. He is also Extraordinary Professor in the Department of Psychiatry at Stellenbosch University. He is a member of the Editorial/Advisory Boards of several national and international addiction journals and participates in the WHO Expert Panel on Drug Dependence and Alcohol Problems, the technical advisory group of the UNODC/WHO joint programme on drug dependence, treatment and care, and the board of the Global Alcohol Policy Alliance. His research interests encompass the epidemiology and burden of disease related to different addictive and sexual behaviours.



Dr. Vladimir Poznyak is currently a Coordinator of the Management of Substance Abuse Unit at the Department of Mental Health and Substance Abuse of the WHO in Geneva. He trained in psychiatry and completed his PhD in Belarus and the Russian Federation, and has also served in professorial positions in psychiatry at the Belarusian State Medical University. Before joining the WHO, he worked on alcohol and drugs at the WHO Regional Office for Europe in Copenhagen, Denmark. His responsibilities in WHO include normative, advocacy, research and country support activities related to alcohol and drugs.




Prof. Alison Ritter is a clinical psychologist, leading drug policy researcher and Director of the Drug Policy Modelling Program (DPMP) at the National Drug and Alcohol Research Centre (NDARC) Australia. The goal of the DPMP is to advance illicit drug policy through improving the evidence-base, developing new policy decision-making tools and understanding the best mix of policy options (law enforcement, prevention, treatment and harm reduction) and the ways in which these different policy options dynamically interact. Current academic interests include identifying alternate policing responses with MDMA, determining amounts for legislative thresholds for serious drug offences, reducing the burden of injecting drug use in Australia and the influence of research on drug policy.

Prof. Laura A. Schmidt is a sociologist and Professor of Health Policy in the School of Medicine at the University of California at San Francisco, USA. She holds a joint appointment in the Philip R. Lee Institute for Health Policy Studies and the Department of Anthropology, History and Social Medicine and is also Co-Director of the Community Engagement and Health Policy Program for UCSF's Clinical and Translational Sciences Institute. Her research focuses on the social determinants of health, and understanding how lifestyle risk factors, such as alcohol and poor diet, influence chronic disease and health inequality, and the use of mixed methods and translational approaches for evidence-based policymaking.



Prof. Robert West is a psychologist and Professor of Health Psychology and Director of Tobacco Studies at University College London, UK. He is also Editor in Chief, of the journal *Addiction* and Assistant Editor of *Addiction Abstracts*. His main research area is nicotine and tobacco use (RCTs on cessation methods, surveys and cohort studies of smoking behaviour, qualitative studies, laboratory studies on the acute effects of stopping and studies to assess and disseminate best practice in smoking cessation clinics), and other research areas include addiction, traffic accidents and health-related behaviour.

Prof. George Woody is a psychiatrist and Professor of Psychiatry at Perelman School of Medicine, University of Pennsylvania, USA, as well as Principal Investigator of the Delaware Valley Node of the NIDA Clinical Trials Network. He was formerly a member of the DSM-IV Work Group on Substance Use Disorders and the FDA Drug Abuse Advisory Committee, Co-editor of Treatment Improvement Protocols on methadone maintenance, and member of RADARS, a research group studying abuse liability of prescription drugs. He has lectured nationally and internationally; participated in HIV and treatment studies in Brazil, Iceland, Indonesia, Republic of Georgia, and the Russian Federation.



In addition, **Jürgen Rehm, Robin Room & Ambros Uchtenhagen** are members of the ALICE RAP project, who, whilst not official members of the GSG, bring their global expertise to the regular working of the project and, similarly, play a role in horizon scanning, internal peer review and quality checks.

You can contact any of the GSG members whose profiles appear here via the coordination team or by logging into the ALICE RAP website and accessing the [participants' contact details](#).